Evrópusambandið - íslenska - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hinsveiflur og heilahimnubólur og hliðstæður - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

boehringer ingelheim vetmedica gmbh* - pergolidum mesýlat - tafla - 1 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

ceva santé animale - gi - hár-loft þvagræsilyf, súlfónamíð, látlaus - hundar - fyrir meðferð klínískum merki tengjast hjartabilun í hunda, þar á meðal í lungum bjúg.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

amneal pharma europe ltd - algengari ddc hemli - parkinsonsveiki - anti-parkinsonslyf - einkenni meðferðar hjá fullorðnum sjúklingum með parkinsonsveiki.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - Önnur meltingarvegi og efnaskipti vörur, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - macimorelin myndir - greiningaraðferðir, annarra - macimorelin - Þetta lyf er eingöngu ætlað til greiningar.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

vétoquinol sa - vatnsfrí torasemíð - súlfónamíð, látlaus, hár-loft þvagræsilyf - hundar - til meðhöndlunar á klínískum einkennum, þ.mt bjúgur og útbrot, tengd hjartabilun hjá hundum.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - kyrningahvítblæði, eitilfrumnafæð, langvarandi, b-frumur - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

tillotts pharma gmbh - budesonidum inn - hart hylki með breyttan losunarhraða - 3 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

abcur ab* - metolazonum inn - tafla - 5 mg